LivaNova PLC Names Chief Operating Officer
(Thomson Reuters ONE) -
LONDON, Aug. 01, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN)
("LivaNova" or the "Company"), a market-leading medical technology and
innovation company, following its announcement of a refined business
implementation model and related organizational structure today announced the
appointment of Damien McDonald as its new Chief Operating Officer (COO). Damien
McDonald brings nearly 30 years of health care experience to LivaNova through
executive leadership roles with Danaher Corporation, Zimmer Holdings and Johnson
& Johnson. Joining LivaNova effective October 3, 2016, McDonald will report to
CEO André-Michel Ballester as a member of the corporation's executive team and
will be domiciled in London.
"We recently announced a new organizational model to ensure that we have the
right resources and structure to implement our strategic priorities," said
André-Michel Ballester, Chief Executive Officer. "Today I am pleased to
announce a critical addition to LivaNova's leadership team with the naming of
Damien McDonald as our new Chief Operating Officer. Damien brings a breadth of
healthcare P&L leadership credentials to LivaNova and a track record of
profitable growth achieved through execution of commercialization strategies
across the globe."
McDonald joins LivaNova from Danaher Corporation where he was Group Executive
and Corporate Vice President. He was Group President of Kerr Corporation,
leading an approximately $1.5 billion dental consumables entity. Prior to that
he led Zimmer's spine division where he helped acquire and successfully
integrate substantial acquisitions. Earlier in his career, he worked with a
number of J&J's Medical Device Franchises, including Ethicon, where he
led marketing of the $2.5 billion medical device unit.
"I am confident that Damien's experience, knowledge and understanding of health
care portfolios along with his track record of executing successful and
profitable growth through an uncompromising focus on commercial leadership and
quality will propel LivaNova's growth," added Ballester.
"I am enormously excited about the growth potential of LivaNova's portfolio of
medical technology businesses," said Damien McDonald. "I look forward to
working with André-Michel and his talented leadership team to capitalize on the
numerous opportunities across the globe and to help accelerate the long-term
strategic goals the company has outlined."
McDonald will be charged with driving innovative products and global expansion
across the organization. His direct reports will include:
* regional leaders in the United States, Europe and Rest of World responsible
for sales and marketing for all company products in their respective
regions,
* product franchise leaders in Neuromodulation, Cardiac Surgery and Cardiac
Rhythm Management responsible for product R&D and alignment of product
marketing activities on a global basis,
* global market access teams responsible for coordinating public and private
reimbursement on a global basis,
* global operations responsible for global manufacturing operations, including
supply chain and purchasing, and
* global customer service responsible for product order processing and
fulfillment.
The transition to our new realigned organization is expected to be completed by
the end of 2016.
About LivaNova
LivaNova PLC is a global medical technology company formed by the merger of
Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and
Cyberonics Inc., a medical device company with core expertise in
neuromodulation. LivaNova transforms medical innovation into meaningful
solutions for the benefit of patients, healthcare professionals, and healthcare
systems. The Company employs approximately 4,600 employees worldwide and is
headquartered in London, U.K. With a presence in more than 100 countries,
LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm
Management, and Neuromodulation, with operating headquarters in Clamart
(France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and is admitted to the standard listing segment of
the Official List of the UK's Financial Conduct Authority and to trading on the
London Stock Exchange (LSE) under the ticker symbol "LIVN".
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of
Section 21E of the United States Securities Exchange Act of 1934, as amended.
Forward-looking statements are not historical facts but are based on certain
assumptions of management and describe our future plans, strategies and
expectations. Forward-looking statements can generally be identified by the use
of forward-looking terminology, including, but not limited to, "may," "could,"
"seek," "guidance," "predict," "potential," "likely," "believe," "will,"
"expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations
of these terms and similar expressions, or the negative of these terms or
similar expressions. Forward-looking statements contained in this press release
are based on information presently available to LivaNova and assumptions that
LivaNova believes to be reasonable, but are inherently uncertain. As a result,
our actual results, performance or achievements may differ materially from those
expressed or implied by these forward-looking statements. Investors are
cautioned that all such statements involve risks and uncertainties, including
without limitation, the factors described in the "Risk Factors" section of
LivaNova's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, and other documents filed from time to time with, and/or
announced or published pursuant to the rules of, the United States Securities
and Exchange Commission and/or the United Kingdom Financial Conduct Authority by
LivaNova, together with the risk that our internal leadership and organizational
realignment will not lead to intended improvements, efficiency or results. This
list of factors is not exhaustive. LivaNova does not give any assurance (1)
that LivaNova will achieve its expectations, or (2) concerning any result or the
timing thereof.
All information in this press release is as of the date of its release.
LivaNova does not undertake or assume any obligation to update publicly any of
the forward-looking statements in this press release to reflect actual results,
new information or future events, changes in assumptions or changes in other
factors affecting forward-looking statements, except to the extent required by
applicable law. If we update one or more forward-looking statements, no
inference should be drawn that we will make additional updates with respect to
those or other forward-looking statements. We caution you not to place undue
reliance on any forward-looking statements, which are made only as of the date
of this press release.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications(at)livanova.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: LivaNova PLC via GlobeNewswire
[HUG#2032143]
Datum: 01.08.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 486544
Anzahl Zeichen: 8556
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"LivaNova PLC Names Chief Operating Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
LivaNova PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
